Opendata, web and dolomites

LuMaSense

A Non-Invasive Test for Guiding Follow–up of Patients with CT-Detected Lung Nodules

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LuMaSense project word cloud

Explore the words cloud of the LuMaSense project. It provides you a very rough idea of what is the project "LuMaSense" about.

transfer    spin    plans    speed    detected    health    nodule    competitors    mature    alone    costly    operation    screening    reduce    care    save    countries    mortality    patients    off    completing    cancerous    placement    noninvasive    combination    market    optimization    action    healthcare    commercially    utilizing    immediately    undergone    16    implication    conducting    company    12    successful    complementary    invasive    covered    urgent    fund    tool    24    treatment    lc    cancer    complexity    translated    ldct    positive    portfolio    idea    prototype    poc    sensitivity    economic    portability    programs    technological    powerful    marketable    unnecessary    diag    stand    optimal    grant    rate    front    technique    false    device    billion    worldwide    ct    stages    specificity    usefulness    rationale    morbidity    distinguish    delay    malignant    96    transform    auxiliary    exists    clinical    evaluation    oriented    breath    group    erc    lung    relies    ip   

Project "LuMaSense" data sheet

The following table provides information about the project.

Coordinator
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY 

Organization address
address: SENATE BUILDING TECHNION CITY
city: HAIFA
postcode: 32000
website: www.technion.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2016-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY IL (HAIFA) coordinator 150˙000.00

Map

 Project objective

This PoC is a commercially-oriented spin-off from our “DIAG-CANCER” ERC project, addressing an urgent clinical need in the field of lung cancer (LC). The rationale behind this PoC is that CT-based LC screening programs are emerging in many countries worldwide. However, the high false positive rate of this technique (96% out of the 24% positive CT findings are non-cancerous) has been a major challenge in front those plans. This is because the CT-detected non-cancerous group has undergone unnecessary invasive procedures that are both costly and associated with significant morbidity and mortality. With this PoC project, we aim to increase the specificity of the LDCT based screening program by utilizing an auxiliary noninvasive breath test to distinguish between malignant and non-cancerous CT findings. The proposed breath test relies on a novel stand-alone device that provide an improved combination of speed, sensitivity, portability, low complexity, easy operation and low production cost. In order to transform our idea and current technology into a marketable device we propose taking several steps: (i) optimization of a prototype device and evaluation of its clinical usefulness through clinical studies; (ii) completing the IP portfolio of the device; and (iii) conducting detailed market research to identify the optimal placement in the healthcare market and possible competitors. After completing these stages, to be covered by the present grant, we propose to proceed to the technology transfer to a mature health care company or through complementary fund to advance the technological plans. If successful, the proposed PoC can be translated immediately into a powerful tool for the management of nodule-positive patients. It will both reduce the rate of unnecessary invasive procedures, and on the other hand, will avoid treatment delay when cancer exists. The economic implication of this action is a significant save of ~$12-16 billion for the healthcare system worldwide.

 Publications

year authors and title journal last update
List of publications.
2016 Inbar Nardi-Agmon, Manal Abud-Hawa, Ori Liran, Naomi Gai-Mor, Maya Ilouze, Amir Onn, Jair Bar, Dekel Shlomi, Hossam Haick, Nir Peled
Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer
published pages: 827-837, ISSN: 1556-0864, DOI: 10.1016/j.jtho.2016.02.017
Journal of Thoracic Oncology 11/6 2019-07-22

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LUMASENSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LUMASENSE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Cu4Peroxide (2020)

The electrochemical synthesis of hydrogen peroxide

Read More  

SPECTRODOT (2018)

Hand-held broadband hybrid graphene-quantum dots spectrometer

Read More  

CUSTOMER (2019)

Customizable Embedded Real-Time Systems: Challenges and Key Techniques

Read More